DrugSorb-ATR system for Postoperative Hemorrhage

Beth Israel Deaconess Medical Center, Boston, MA
Targeting 3 different conditionsDrugSorb-ATR system +1 moreN/AWaitlist AvailableLed by C. M Gibson, MDResearch Sponsored by CytoSorbents, Inc

Study Summary

This trial will test a new method to reduce the risk of serious bleeding in patients taking blood thinners who need urgent surgery.

Eligible Conditions
  • Postoperative Hemorrhage
  • Hemorrhage
  • Blood Loss


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the first day post-operation
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the first day post-operation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of perioperative bleeding
Secondary outcome measures
Chest tube drainage
DOAC drug removal: apixaban
DOAC drug removal: rivaroxaban
+7 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: DrugSorb-ATR InterventionExperimental Treatment1 Intervention
Standard of care + DrugSorb-ATR system
Group II: ControlPlacebo Group1 Intervention
Standard of care with Sham set-up

Find a site

Who is running the clinical trial?

CytoSorbents, IncLead Sponsor
16 Previous Clinical Trials
4,516 Total Patients Enrolled
2 Trials studying Postoperative Hemorrhage
640 Patients Enrolled for Postoperative Hemorrhage
C. M Gibson, MDPrincipal Investigator
Beth Israel Deaconess Medical Center, The Baim Institute, and Harvard Medical School
1 Previous Clinical Trials
140 Total Patients Enrolled
1 Trials studying Postoperative Hemorrhage
140 Patients Enrolled for Postoperative Hemorrhage
Michael J Mack, MDPrincipal Investigator
Baylor Scott & White The Heart Hospital
2 Previous Clinical Trials
240 Total Patients Enrolled
1 Trials studying Postoperative Hemorrhage
140 Patients Enrolled for Postoperative Hemorrhage

Media Library

DrugSorb-ATR system Clinical Trial Eligibility Overview. Trial Name: NCT05093504 — N/A
DrugSorb-ATR system 2023 Treatment Timeline for Medical Study. Trial Name: NCT05093504 — N/A
Postoperative Hemorrhage Patient Testimony for trial: Trial Name: NCT05093504 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical trial being conducted in numerous places across North America?

"This study is enrolling patients from 28 different sites, such as Bethesda North Hospital and TriHealth Inc. in Cincinnati. Additionally, the University of Colorado Denver and the University of Mississippi Jackson are also participating locations."

Answered by AI

Is enrollment in this clinical trial still available?

"The clinical trial in question, posted on December 27th 2021 and last modified on November 17th 2022, is not presently taking partakers. Nevertheless, there are 372 other medical studies that are currently recruiting patients."

Answered by AI

Who else is applying?

What state do they live in?
What site did they apply to?
University of California, Davis Medical Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?

Why did patients apply to this trial?

Since I have to thinners, I’d like to be able help somebody else if possible.
~10 spots leftby Dec 2023